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Forkhead-associated (FHA) domains are modular protein±protein
interaction domains of 130 amino acids present in numerous
signalling proteins. FHA-domain-dependent protein interactions are
regulated by phosphorylation of target proteins and FHA domains
may be multifunctional phosphopeptide-recognition modules. FHA
domains of the budding yeast cell-cycle checkpoint protein kinases
Dun1p and Rad53p have been crystallized. Crystals of the Dun1-
FHA domain exhibit the symmetry of the space group P6122 or
P6522, with unit-cell parameters a = b = 127.3, c = 386.3 AÊ ; diffraction
data have been collected to 3.1 AÊ resolution on a synchrotron source.
Crystals of the N-terminal FHA domain (FHA1) of Rad53p diffract
to 4.0 AÊ resolution on a laboratory X-ray source and have Laue-
group symmetry 4/mmm, with unit-cell parameters a = b = 61.7,
c = 104.3 AÊ .
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1. Introduction
Many signalling molecules contain non-
catalytic modules as part of their polypeptide
chains and these modules play crucial roles in
accomplishing the assembly of signalling
complexes (Pawson & Scott, 1997). The
forkhead-associated (FHA) domains are one
class of protein-interaction modules present in
a diverse set of over 120 signalling proteins,
covering all phyla from bacteria, yeast and
plants to mammals (Hofmann & Bucher,
1995). In human cells, FHA domains seem to
be particularly prevalent in so-called check-
point proteins that delay the cell cycle in
response to replicational stress and DNA
damage (e.g. Chk2, Nbs1) or mitotic spindle-
assembly defects (e.g. CHFR; Scolnick &
Halazonetis, 2000). This way, FHA domain-
containing proteins act as tumour-suppressor
molecules and their mutation leads to a genetic
predisposition to cancer. For example, the
FHA-domain-containing protein kinase Chk2
is mutated in a subset of patients suffering
from the Li±Fraumeni multicancer syndrome
(usually caused by mutations in p53; Bell et al.,
1999) and disease-causing mutations in the
FHA-domain-containing protein Nbs1 are
documented in a large subset of patients with
Nijmegen breakage syndrome (Carney et al.,
1998). The importance of FHA-domain-
containing checkpoint proteins is further illu-
strated by the fact that they, as well as the
respective signalling pathways, are highly
conserved throughout evolution from the
yeasts Saccharomyces cerevisiae and S. pombe
to humans (Elledge, 1996; Rhind & Russel,
1998).
Dun1p and Rad53p are budding yeast
homologues of the human Chk2 kinase. While
Dun1p has a similar topology to Chk2 with a
single FHA domain located N-terminal to the
kinase catalytic domain, Rad53p contains FHA
domains both N-terminal (FHA1) as well as
C-terminal (FHA2) to the kinase domain. The
FHA2 domain is essential for the DNA
damage-induced activation of Rad53p by
mediating its interaction with phosphorylated
Rad9p in vivo (Sun et al., 1998). The in vivo
function of the FHA1 domain is unknown, but
recent evidence indicates that it can directly
bind to phosphothreonine-containing peptides
in vitro (Durocher et al., 1999). Based on
overexpression experiments, the Dun1-FHA
domain appears to be involved in the Dun1-
dependent transcriptional induction of repair
enzymes in response to replication blocks in
vivo (Hammet et al., 2000). The recent NMR
structure of the Rad53-FHA2 domain has
provided the ®rst insight into the overall
structure of FHA domains (Liao et al., 1999).
The core of the FHA2 domain is formed by an
11-stranded -sandwich similar to the MH2
domain of smad transcription factors. The
FHA2 domain also interacts with phospho-
tyrosine, indicating that FHA domains may be
multifunctional phosphopeptide-binding
modules. The NMR structure as well as recent
biochemical studies (Hammet et al., 2000) have
demonstrated that FHA domains in yeast
checkpoint kinases contain >130 amino-acid
residues and are therefore considerably larger
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than the 55±75 amino-acid segment
predicted by sequence comparisons.
However, based on limited proteolysis
experiments the Dun1-FHA and Rad53-
FHA1 domains seem to contain some 20
residues at the N-terminus that are missing
from the stable Rad53-FHA2 fragment
(573±730) used for the NMR structure. To
further our understanding of FHA domain
structures and ultimately of the mechanism
of phosphopeptide recognition by these
modules, we have initiated structural
studies of the Dun1-FHA and Rad53-
FHA1 domains, both containing extended
N-terminal regions compared with the
FHA2 fragment in the NMR structure. This
report describes the preliminary crystallo-
graphic characterization of these domains.
2. Materials and methods
2.1. Protein expression and purification
Constructs corresponding to proteo-
lytically stable FHA domains (residues 19±
159 of Dun1p; residues 20±164 of Rad53p)
were generated by the polymerase chain
reaction. These fragments were cloned into
pQE60 and expressed and puri®ed essen-
tially as described previously for larger
fragments (Hammet et al., 2000).
2.2. Crystallization
Crystallization conditions were screened
by the sparse-matrix approach and an
ammonium sulfate grid screen using the
hanging-drop vapour-diffusion technique
(Jancarik & Kim, 1991; McPherson, 1982) at
277 and 293 K. After 1 d, very small crystals
(0.01  0.02  0.02 mm) of Dun1-FHA
grew when combining an equal ratio of
protein solution (11.5±14 mg mlÿ1 in 20 mM
imidazole at pH 7.0) and reservoir solution
consisting of 2.4 M (NH4)2SO4 and
suspending over 1.0 ml of the reservoir
solution at 293 K. The crystals have a
hexagonal morphology (Fig. 1) and repeated
macroseeding was required to increase the
crystal size to 0.1 0.2 0.2 mm. Crystals of
Rad53-FHA1 were obtained after 2 d when
combining an equal ratio of protein solution
(15 mg mlÿ1) and reservoir solution
consisting of 0.1 M HEPES pH 7.5,
10%(v/v) 2-propanol and 20%(w/v) poly-
ethylene glycol 4000 at 293 K. However,
these crystals were of poor morphology and
diffraction quality. Modi®cation of these
conditions to 0.1 M HEPES pH 7.0,
10%(v/v) 2-propanol or ethanol, 18%(w/v)
polyethylene glycol 4000 and 277 K yielded a
few crystals suitable for X-ray crystallo-
graphic studies after two months.
2.3. X-ray data collection and processing
A crystal of Dun1-FHA with dimensions
of 0.1 0.2 0.2 mm was transiently soaked
in cryoprotectant solution containing 30%
glycerol and 2.4 M (NH4)2SO4. The crystal
was ¯ash-cooled at 100 K in a nitrogen
stream (Oxford Cryosystems Cryostream)
and X-ray diffraction data were collected at
Stanford Synchrotron Radiation Laboratory
(SSRL) beamline 9-1 ( = 0.97 AÊ ) using a
MAR Research 345 image-plate detector.
The data-collection strategy incorporated
oscillation angles of 0.25, 0.5 and 1 in order
to accommodate regional variations in
overlapping re¯ections and exposure times
of 45±180 s. Data were processed at 3.1 AÊ
resolution and scaled using the programs
DENZO and SCALEPACK (Otwinowski &
Minor, 1997); the statistics are given in
Table 1.
A crystal of Rad53-FHA1 with dimen-
sions of 0.2 0.1 0.05 mm was mounted in
a quartz capillary and X-ray diffraction data
were collected at 290 K using Cu K
radiation from a Rigaku RU-200 X-ray
generator operating at 90 mA and 50 kV
with a MAR Research 345 imaging-plate
detector. Initially the crystals diffracted to
3 AÊ resolution, but the high-
resolution diffraction rapidly
weakened during the data
collection owing to radiation
damage. Data were processed
and scaled at 4.0 AÊ resolution
(Table 1) using the programs
DENZO and SCALEPACK
(Otwinowski & Minor, 1997).
3. Results and discussion
The Dun1p FHA data set
(Table 1) is 98.2% complete at
3.1 AÊ and is reasonably complete
(>95%) throughout all resolu-
tion shells, with 72% of data
having I > 3(I). The crystals exhibit a
hexagonal lattice, with unit-cell parameters
a = b = 127.3, c = 386.3 AÊ . The Laue
symmetry of 6/mmm was indicated clearly
from scaling statistics; systematic absences
along the sixfold axis enabled distinction
between P6122/P6522 (l = 6n) and P6222/
P6422 (l = 3n). Assuming 12 molecules of
Dun1-FHA (the molecular mass of Dun1-
FHA is 17 233 Da) per asymmetric unit, the
VM (Matthews, 1968) is 2.2 AÊ
3 Daÿ1, corre-
sponding to a crystal solvent content of 44%.
Molecular-replacement calculations (Colla-
borative Computational Project, Number 4,
1994; MOLREP; Vagin & Teplyakov, 1997)
are being attempted using a homology
model derived from the NMR structure of
Rad53-FHA2 (Liao et al., 1999). Simulta-
neously, we are attempting to prepare
heavy-atom derivative crystals and also a
selenomethionine-labelled derivative of
Dun1-FHA, which contains one methionine.
We aim to determine these structures using
the techniques of multiple isomorphous
replacement (MIR), molecular replacement
(MR) and multi-wavelength anomalous
dispersion (MAD).
The Rad53-FHA1 data set (Table 1) is
93.3% complete at 4.0 AÊ ; however, the data
are weak [45% of data with I > 3(I)] and
merge poorly (Rmerge = 33.0%) as a conse-
quence of the radiation damage to the
crystal. The crystals have a tetragonal lattice,
with unit-cell parameters a = b = 61.7,
c = 104.3 AÊ . Owing to the insuf®cient data
information on systematic absences it is not
possible to determine the space group at this
stage. However, the Laue group symmetry is
4/mmm as determined from data scaling
statistics. Assuming one monomer of Rad53-
FHA1 (molecular mass of 17 289 Da) in the
asymmetric unit, the VM (Matthews, 1968)
value is 2.9 AÊ 3 Daÿ1, corresponding to a
crystal solvent content of 57%. Attempts to
Figure 1
Crystal of Dun1-FHA with approximate dimensions
of 0.1  0.2  0.2 mm.
Table 1
X-ray diffraction data-collection statistics of Dun1-FHA and
Rad53-FHA1 domains.
Values in parentheses represent the highest resolution shell.
Dun1p FHA Rad53p FHA1
Space group P6122 or P6522 Laue group 4/mmm
Unit-cell parameters (AÊ ) a = b = 127.3,
c = 386.3
a = b = 61.7,
c = 104.3
Resolution range (AÊ ) 100±3.1 (3.21±3.10) 30.0±4.0 (4.14±4.00)
Measured re¯ections 1521431 12002
Unique re¯ections 34158 (3376) 1816 (178)
Completeness (%) 98.2 (99.9) 93.3 (94.2)
Average I/(I) 21.1 (2.7) 4.6 (1.9)
Rmerge² (%) 10.8 (98.8) 33.0 (76.9)
² Rmerge =
P
hkl 
P
ijIhkl;i ÿ hIhkl;iij/
P
hkl;ihIhkli, where Ihkl,i is the intensity of
an individual measurement of the re¯ection with Miller indices h, k and l, and
hIhkli is the average intensity of that re¯ection calculated for I > ÿ3(I).
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solve the crystal structure by molecular
replacement are in progress, as are further
crystallization experiments to obtain
suitable crystals for cryocooled X-ray data
collection and improved data quality.
Structural studies of FHA domains alone
and in complex with phosphorylated target
peptides will provide atomic details of the
interactions that facilitate recognition and
binding between these non-catalytic
modules and their protein partners. Conse-
quently, this will contribute to the under-
standing of the mechanism of formation
of protein signalling complexes and the
regulation of complex cellular signalling
pathways.
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